
PainChek® receives Singapore regulatory clearance, signs landmark agreement with Allium Healthcare, Singapore's first purpose-built premium nursing home

Highlights:

- **PainChek® receives regulatory clearance from Singapore's Health Sciences Authority (HSA) for use of its products in Singapore**
- **Singapore's first purpose-built premium nursing home developer and operator, Allium Healthcare, signs two-year licence agreement with PainChek®**
- **Singapore regulatory approval and first direct PainChek® commercial agreement to open up broader Asian market opportunities**
- **Study finds 82,000 people living in Singapore in 2018 may have dementia, with the number expected to exceed 100,000 in a few years' time¹.**
- **Currently, there are 23 million people with dementia in Asia, with Asia expected to see the second largest increase globally in numbers of people with dementia by 2030²**

Sydney, 6th August 2019. PainChek® Ltd (ASX: PCK) ("PainChek®" or "the Company"), developer of the world's first smart phone-based pain assessment and monitoring application, continues to rapidly advance its international expansion strategy with receipt of a key Asian regulatory clearance and the signing of a landmark commercial agreement.

The Company has received regulatory approval from Singapore's Health Sciences Authority ("HSA") for the use of the PainChek® application in the market. It has also entered a two-year licence agreement with leading Singapore aged care provider, Allium Healthcare Holdings Pte Ltd ("Allium").

Allium is the developer and operator of *Allium Care Suites*, Singapore's first purpose-built premium 129 bed nursing home, scheduled to welcome its first resident later this year. In addition, Allium operates two other day care facilities, *Allium Care Studio*, which also provide personalised home care services for older persons who prefer being treated at home. Under the first phase of the agreement, Allium will utilise PainChek® across all these facilities on the standard PainChek license terms.³

"We provide personalised and dignified care to our clients and explore evidence-based technology that can help us achieve that goal better and more accurately," said Allium Healthcare's Chief Executive Officer, Mr Bernie Poh.

1 www.alz.org.sg/dementia/singapore/

2 www.alz.co.uk/sites/default/files/conf2018/3_DY_Suharya_Asia_Pacific_response_to_global_action_plan_on_dementia.pdf

3 The PainChek monthly Revenue per Licensed Bed (ARLB) across the RAC customers based on the agreements signed to date is in the range of \$5 AUD per month, and the Revenue per Active Resident (ARAR) is in the range of \$10 AUD per month based on actual resident usage. See ASX release dated 31 July 2018.

“The PainChek® App provides us with the capability to better assess and quantify our clients’ pain levels so that we can enhance their treatment plans. We also see great opportunity to work with PainChek® as part of our integrated care offering across our nursing home, day care centres and home care services, especially for older persons living with dementia and communication difficulties.” he added.

PainChek®’s Managing Director, Mr Philip Daffas believes this agreement, a first entry for PainChek® into Singapore, can be a platform for the broader Asian markets, where there is a large ageing population.

“We have recently received clearance for PainChek® from Singapore’s regulatory body. This is a great first step into the market with Allium Healthcare,” said Mr Daffas.

“Many people in Asia living with dementia have a desire to remain living at home and often have good family support. The PainChek® Shared Care programme will provide the capability for Allium to provide accurate pain assessments across the continuum of care and help those people live life the way they want to.”

According to the 2015 *Well-being of the Singapore Elderly* (WiSE) study led by Singapore’s Institute of Mental Health in 2015, one in ten people aged 60 and above may have dementia. This translates to almost 82,000 people in 2018 and the number is expected to exceed 100,000 in a few years’ time.

A recent study conducted by the Alzheimer’s Disease International found that there were 23 million people with dementia in Asia, with Asia expected to see the second greatest increase in numbers of people with dementia by 2030⁴.

Recent Developments

The PainChek® Adult App is clinically validated⁵ and regulatory-cleared⁶ technology that uses automated facial recognition and analysis to identify, quantify and monitor pain in adults that are unable to verbalise their pain.

The PainChek® Adult App is now in clinical use in more than 80 residential aged care homes across Australia helping to better assess pain severity levels for residents living with dementia and cognitive impairment. Earlier this year, the Australian Federal Government announced it will invest A\$5M to facilitate the implementation of the company’s pain recognition app in Australian Aged Care Facilities⁷. The Company has also entered the United Kingdom market through a distribution agreement with leading Aged Care software provider Person Centred Software⁸.

PainChek® has also announced it will be collaborating with Murdoch Children’s Research Institute (MCRI), to clinically test a version of the PainChek® App for infants⁹.

4 www.alz.co.uk/sites/default/files/conf2018/3_DY_Suharya_Asia_Pacific_response_to_global_action_plan_on_dementia.pdf

5 Atee M, Hoti K, Hughes JD. A Technical Note on the PainChek™ System: A Web Portal and Mobile Medical Device for Assessing Pain in People With Dementia. *Front Aging Neurosci.* 2018 Jun 12;10:117. doi: 10.3389/fnagi.2018.00117. eCollection 2018.

6 PainChek® Adult App has TGA and CE Mark regulatory clearances as a Class 1 Medical Device

7 ASX release dated 29 April 2019

8 ASX release dated 27 May 2019

9 ASX announcement dated 2 July 2019

The PainChek® Infant *PainFaces* study will be led by Professor Franz Babl (MCRI) and Associate Professor Di Crellin (MCRI) in the Emergency Department (ED) of the Royal Children's Hospital, Melbourne. Lead researcher on the project Associate Professor Crellin has recently evaluated the validity and reliability of two observational children's pain assessment tools, the Face, Legs, Activity, Cries and Consolability (FLACC) scale and the Modified Behavioural Pain Scale (MBPS), in assessing procedural pain in the ED.

In this new study, which is expected to commence later this month, the pain scores derived using the PainChek® Infant App will be compared to those obtained using the FLACC by two independent assessors in approx. 100 infants undergoing painful procedures within the ED.

Ends

For further information please contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290

Philip Daffas
Managing Director
Tel: +61 406-537-235

www.painchek.com

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

PainChek® is a smart-phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person's face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.


PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com



PainChek® artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain.



PainChek® domains of pain assessment that calculates pain severity score.

About Allium Healthcare

Allium Healthcare Holdings Pte Ltd is a wholly-owned subsidiary of investment holding company G. K. Goh Holdings Limited which co-owns Opal Aged Care, a leading specialist aged care provider in Australia, caring for 6,500 residents in 74 homes. Allium Healthcare is the developer and operator of *Allium Care Suites*, Singapore's first purpose-built 129-bed premium nursing home, scheduled to welcome its first resident later this year. The Home, which will comprise exclusively of single and double rooms with ensuite facilities, will introduce a new model of bespoke personalised care, uniting healthcare and hospitality. Allium's other facilities include *Allium Care Studio*, two day care centres, which also provide personalised home care services for older persons who prefer being treated at home. These include physiotherapy, geriatric care management, caregiver training and other nurse-led home care services.

For more information, visit <http://www.alliumhealthcare.com>